JADO Technologies GmbH Report issue

Contributed to NME For profit Phase 2
Founded: Dresden Germany (2001)
Status: Defunct (2013)

Organization Overview

First Clinical Trial
2007
NCT00457288
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

miltefosine (impavido) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Mastocytoma (Phase 2)

Mastocytosis (Phase 2)

Mastocytosis, Cutaneous (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1